Contrast

DRUG5 trials

Sponsors

Astellas Pharma Inc, Sun Yat-sen University, Cedars-Sinai Medical Center, Medical University of South Carolina

Conditions

Brain LesionsContrast Induced NephropathyCoronary Artery DiseaseCoronary Artery Disease (CAD)Coronary AtherosclerosisCoronary Microvascular Disease

Phase 2

A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)

CompletedNCT01334918

Astellas Pharma IncCoronary Artery Disease (CAD)

Start: 2011-04-26End: 2012-07-02Updated: 2024-12-04

Unknown Phase

Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial

CompletedNCT02650336

Sun Yat-sen UniversityContrast Induced Nephropathy

Start: 2013-10-31End: 2015-09-30Updated: 2016-01-08

Whole-Heart Myocardial Blood Flow Quantification Using MRI

Cedars-Sinai Medical CenterCoronary Artery Disease, Coronary Microvascular Disease

Start: 2018-03-01End: 2025-01-01Target: 160Updated: 2023-02-08

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

RecruitingNCT03504956

Cedars-Sinai Medical CenterCoronary Atherosclerosis

Start: 2018-07-30End: 2027-12-31Target: 150Updated: 2026-08-21

DYNA EMBOLIZATION - Pilot Study of IV Dyna CT and CBV Imaging Techniques

CompletedNCT03528200

Medical University of South CarolinaBrain Lesions

Start: 2015-07-31End: 2021-01-22Updated: 2021-02-01